Patheon inks Boehringer deal

- Last updated on GMT

Patheon is supporting development of two Boehringer Ingelheim type II diabetes treatments in a three-year, $18m (€13m) deal.

Canada-based Patheon will provide services to help develop two fixed-dose combination products. Boehringer is developing the products for type II diabetics. Further details of the role Patheon will have in development are yet to emerge.

I am very gratified that Boehringer Ingelheim recognizes our expertise in formulating, scaling and successfully launching complex formulations such as these molecules​”, Mark Kontny, president of pharmaceutical development services and chief scientific officer at Patheon, said.

Patheon expects demand for development services to grow as biopharm cuts in-house capacity. As part of its reorganisation​ Patheon plans to invest in earlier stage development capabilities and Europe.

Related topics: Contract Manufacturing

Related news

Show more